Epidemiological Characteristics and Clinical Impact of Macrolide‐Resistant Mycoplasma pneumoniae Infection in Children in Southwest China, 2021–2025
Open Access
- 30 September 2026
- journal article
- research article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 20 (10) , e70233
Abstract
Background: Mycoplasma pneumoniae (MP) is a key pathogen causing pediatric community‐acquired pneumonia. Increasing macrolide resistance poses considerable clinical challenges. This study investigated MP epidemiology and macrolide resistance in children aged 0–14 years in Southwest China from 2021–2025. Methods: Retrospective analysis of MP antibody, nucleic acid, and resistance gene detection data. MP infections were categorized into macrolide‐resistant (MRMP) and macrolide‐sensitive (MSMP) groups. Clinical information was collected and compared. Results: Positive rates for MP‐RNA, DNA, IgM, and total antibodies were 12.43%, 9.82%, 30.19%, and 49.82%, respectively. Infections predominantly affected children aged 2–8 years. The macrolide resistance rate was 87.87%. Compared with the MSMP group, the MRMP group had longer hospital stays (+0.74 days), higher rates of fiberoptic bronchoscopy (+19.6%), and a significantly higher initial macrolide treatment failure rate, leading to increased doxycycline use (+20.8%). Conclusion: MRMP infections are highly prevalent in Southwest China and are associated with more complex clinical conditions and worse outcomes. Early resistance gene detection is recommended for hospitalized children with suspected MP infection during epidemic seasons. For children aged 2–8 years with persistent high fever and imaging findings of lung consolidation or mucus plugs, high suspicion of MRMP is warranted, and timely fiberoptic bronchoscopy should be considered.Keywords
This publication has 23 references indexed in Scilit:
- Genomic‐Based Epidemiological Analysis of the Post‐Pandemic Mycoplasma pneumoniae ResurgenceMedcomm, 2026
- Mycoplasma pneumoniae incidence, phenotype, and severity in children and adolescents in Denmark before, during, and after the COVID-19 pandemic: a nationwide multicentre population-based cohort studyThe Lancet Regional Health - Europe, 2024
- Persistent high macrolide resistance rate and increase of macrolide-resistant ST14 strains among Mycoplasma pneumoniae in South Korea, 2019–2020Journal of Microbiology, Immunology and Infection, 2022
- Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae InfectionsJAMA Network Open, 2022
- Molecular features and antimicrobial susceptibility of Mycoplasma pneumoniae isolates from paediatric inpatients in Weihai, ChinaJournal of Global Antimicrobial Resistance, 2022
- Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Southern TaiwanPediatrics & Neonatology, 2021
- Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010–2019Journal of the Formosan Medical Association, 2021
- Antimicrobial therapy of macrolide-resistantMycoplasma pneumoniaepneumonia in childrenExpert Review of Anti-infective Therapy, 2017
- Mycoplasma pneumoniae infection: BasicsJournal of General and Family Medicine, 2017
- Community-Acquired Pneumonia Requiring Hospitalization among U.S. ChildrenNew England Journal of Medicine, 2015